and why won't it get it,they're already fast tracked? Only one in the space too which is set to grow to $15 billion in the near future. Some better read up on DARA real quick while it's still this cheap.
• KRN5500 is a novel, spicamycin derived, non-opioid-non-narcotic analgesic
• Presently, no drug FDA approved for chemotherapy induced peripheral neuropathy (CIPN)
• U.S. Food and Drug Administration (FDA) has been granted Fast Track designation for the treatment of chemotherapy-induced neuropathic pain in patients with cancer.
• Market potential estimated at $2.5B - $2.9B for CIPN
• KRN5500 favorable results from a phase 2a in cancer patients
o Patients failed on 2 previous therapies before treated w/KRN
o KRN5500 met primary endpoints: reduction of pain and safety
o Significantly more effective than placebo (p=0.03)
o Transient and manageable GI side effects
o National Cancer Institute (NCI) entered into a non-exclusive Clinical Trail Agreement with DARA based on phase 2a results
o Phase 2 safety and efficacy study results of KRN5500 for the treatment of neuropathic pain in patients with cancer study published in the Journal of Pain and Symptom Management, an internationally respected, peer-reviewed journal.
jd is just some whacked out pumper. Ignore his / her ramblings.
KRN could be a valuable asset, just depends on two things: positive clinical data moving forward and how will DARA manage the asset., ie will they be able to find a partner to pay the price to move it through clinical trials or do they think they have the will and the ability to move it forward themselves.